NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure
07 juin 2024 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., June 07, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Reports First Quarter 2024 Financial Results
22 mai 2024 08h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., May 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
21 mai 2024 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., May 21, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Announces New Medical Policy Coverage For Nearly Six Million Lives in Florida
16 mai 2024 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., May 16, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024
15 mai 2024 16h30 HE
|
NeurAxis, Inc.
CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Announces New Medical Policy Coverage in North Dakota
23 avr. 2024 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
09 avr. 2024 16h05 HE
|
NeurAxis, Inc.
CARMEL, Ind., April 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024
01 avr. 2024 16h15 HE
|
NeurAxis, Inc.
CARMEL, Ind., April 01, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...
NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry
27 mars 2024 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., March 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...
NeurAxis Announces Highmark BCBS Policy Coverage
11 mars 2024 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., March 11, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...